J Molner Drug Patent Portfolio
J Molner owns 2 orange book drugs protected by 10 US patents Given below is the list of J Molner's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7947739 | Tranexamic acid formulations | 04 Mar, 2025 | Expired |
| US8022106 | Tranexamic acid formulations | 04 Mar, 2025 | Expired |
| US8273795 | Tranexamic acid formulations | 04 Mar, 2025 | Expired |
| US8487005 | Tranexamic acid formulations | 04 Mar, 2025 | Expired |
| US8791160 | Tranexamic acid formulations | 04 Mar, 2025 | Expired |
| US8809394 | Tranexamic acid formulations | 04 Mar, 2025 | Expired |
| US8957113 | Tranexamic acid formulations | 04 Mar, 2025 | Expired |
| US9060939 | Tranexamic acid formulations | 04 Mar, 2025 | Expired |
| US5500413 | Process for manufacture of 1-deamino-8-D-arginine vasopressin | 29 Jun, 2013 | Expired |
| US5763407 | High-purity desmopressin produced in large single batches | 29 Jun, 2013 | Expired |
Latest Legal Activities on J Molner's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of J Molner.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 26 Dec, 2024 | US8487005 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 17 Nov, 2023 | US8273795 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 04 Nov, 2022 | US8022106 (Litigated) |
|
Correspondence Address Change
Critical
| 18 Oct, 2022 | US8791160 |
| Correspondence Address Change | 18 Oct, 2022 | US8957113 |
|
Correspondence Address Change
Critical
| 18 Oct, 2022 | US8273795 |
|
Correspondence Address Change
Critical
| 18 Oct, 2022 | US8809394 |
|
Correspondence Address Change
Critical
| 18 Oct, 2022 | US9060939 |
|
Correspondence Address Change
Critical
| 18 Oct, 2022 | US8487005 |
|
Correspondence Address Change
Critical
| 18 Oct, 2022 | US8022106 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 16 Aug, 2022 | US9060939 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 16 Aug, 2022 | US7947739 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 16 Aug, 2022 | US8957113 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 06 Jan, 2022 | US8791160 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 06 Jan, 2022 | US8809394 |
J Molner's Family Patents
J Molner Drug List
Given below is the complete list of J Molner's drugs and the patents protecting them.
1. Ddavp
Ddavp is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5500413 | Process for manufacture of 1-deamino-8-D-arginine vasopressin |
29 Jun, 2013
(13 years ago)
| Expired |
| US5763407 | High-purity desmopressin produced in large single batches |
29 Jun, 2013
(13 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ddavp's drug page
2. Lysteda
Lysteda is protected by 8 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7947739 | Tranexamic acid formulations |
04 Mar, 2025
(1 year, 4 months ago)
| Expired |
| US8022106 | Tranexamic acid formulations |
04 Mar, 2025
(1 year, 4 months ago)
| Expired |
| US8273795 | Tranexamic acid formulations |
04 Mar, 2025
(1 year, 4 months ago)
| Expired |
| US8487005 | Tranexamic acid formulations |
04 Mar, 2025
(1 year, 4 months ago)
| Expired |
| US8791160 | Tranexamic acid formulations |
04 Mar, 2025
(1 year, 4 months ago)
| Expired |
| US8809394 | Tranexamic acid formulations |
04 Mar, 2025
(1 year, 4 months ago)
| Expired |
| US8957113 | Tranexamic acid formulations |
04 Mar, 2025
(1 year, 4 months ago)
| Expired |
| US9060939 | Tranexamic acid formulations |
04 Mar, 2025
(1 year, 4 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lysteda's drug page